Symdeko (copackaged), Symkevi(tezacaftor)
Alyftrek, Kaftrio, Symkevi (tezacaftor) is a small molecule pharmaceutical. Tezacaftor was first approved as Symkevi on 2018-10-31. It has been approved in Europe to treat cystic fibrosis. It is known to target cystic fibrosis transmembrane conductance regulator.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Combinations
Alyftrek
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Deutivacaftor
+
Tezacaftor
+
Vanzacaftor calcium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ALYFTREK | Vertex Pharmaceuticals | N-218730 RX | 2024-12-20 | 2 products, RLD, RS |
Elexacaftor
+
ivacaftor
+
tezacaftor
+
Ivacaftor
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRIKAFTA (COPACKAGED) | Vertex Pharmaceuticals | N-217660 RX | 2023-04-26 | 2 products, RLD, RS |
| TRIKAFTA (COPACKAGED) | Vertex Pharmaceuticals | N-212273 RX | 2019-10-21 | 2 products, RLD, RS |
Ivacaftor
+
Ivacaftor
+
tezacaftor
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SYMDEKO (COPACKAGED) | Vertex Pharmaceuticals | N-210491 RX | 2018-02-12 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| alyftrek | New Drug Application | 2025-01-31 |
| symdeko | New Drug Application | 2025-02-13 |
| trikafta | New Drug Application | 2025-02-12 |
| vanzacaftor, tezacaftor, and deutivacaftor | New Drug Application | 2024-12-26 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| cystic fibrosis | EFO_0000390 | D003550 | E84 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
99 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fibrosis | D005355 | — | — | 5 | 13 | 39 | 1 | 29 | 85 |
| Drug interactions | D004347 | — | — | — | — | — | 1 | — | 1 |
| Bronchiectasis | D001987 | — | J47 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 11 | 13 | 39 | — | 36 | 97 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Paranasal sinus diseases | D010254 | — | — | — | — | — | — | 2 | 2 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | — | — | — | 2 | 2 |
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 1 | 1 |
| Respiratory signs and symptoms | D012818 | — | — | — | — | — | — | 1 | 1 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 1 | 1 |
| Bacterial infections | D001424 | — | A49 | — | — | — | — | 1 | 1 |
| Symptom flare up | D000067251 | — | — | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tezacaftor |
| INN | tezacaftor |
| Description | Tezacaftor is a drug used for the treatment of cystic fibrosis (CF) in people six years and older, who have a F508del mutation, the most common type of mutation in the CFTR gene. It is sold as a fixed-dose combination with ivacaftor under the brand name Symdeko. It was approved by the U.S. FDA in 2018. The combination of elexacaftor, tezacaftor, and ivacaftor is being sold as Trikafta.
|
| Classification | Small molecule |
| Drug class | cystic fibrosis transmembrane regulator (CFTR) protein modulators |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(CO)c1cc2cc(NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c(F)cc2n1C[C@@H](O)CO |
Identifiers
| PDB | — |
| CAS-ID | 1152311-62-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3544914 |
| ChEBI ID | — |
| PubChem CID | 46199646 |
| DrugBank | DB11712 |
| UNII ID | 8RW88Y506K (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CFTR
CFTR
Organism
Homo sapiens
Gene name
CFTR
Gene synonyms
ABCC7
NCBI Gene ID
Protein name
cystic fibrosis transmembrane conductance regulator
Protein synonyms
ATP-binding cassette sub-family C member 7, cAMP-dependent chloride channel, Channel conductance-controlling ATPase, cystic fibrosis transmembrane conductance regulating, cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)
Uniprot ID
Mouse ortholog
Cftr (12638)
cystic fibrosis transmembrane conductance regulator (Q9JKQ6)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,144 documents
View more details
Safety
Black-box Warning
Black-box warning for: Alyftrek, Trikafta, Vanzacaftor, tezacaftor, and deutivacaftor
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
17,888 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use